{"id":"W3134020977","doi":"10.1172/jci.insight.95042","title":"Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva","year":2021,"lang":"en","type":"article","venue":"JCI Insight","topic":"Heterotopic Ossification and Related Conditions","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Center for Advancing Translational Sciences; Medical Research Council; University of Oxford; Genentech; Innovative Medicines Initiative; Fondation Leducq; Wellcome Trust; Cancer Research UK; Novartis Pharma; Francis Crick Institute; Ontario Genomics Institute; European Federation of Pharmaceutical Industries and Associations; International Fibrodysplasia Ossificans Progressiva Association; National Institutes of Health; Ontario Genomics; Fundação de Amparo à Pesquisa do Estado de São Paulo; U.S. Department of Defense; Diamond Light Source; Genome Canada; National Heart, Lung, and Blood Institute; Pfizer; Harvard Stem Cell Institute; McGill University","keywords":"Fibrodysplasia ossificans progressiva; Heterotopic ossification; Medicine; Myositis ossificans; Bone morphogenetic protein; Soft tissue; Bioinformatics; Internal medicine; Cancer research; Pathology; Anatomy; Genetics; Biology; Gene","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001389971,0.0001545664,0.0003334665,0.00006718851,0.0001970298,0.00005546654,0.00009964699,0.0002885535,0.0008931147],"category_scores_gemma":[0.0002119641,0.0001242162,0.0002032826,0.000215709,0.0001292431,0.00008449457,0.00002055988,0.0003291937,0.0001750153],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003542639,"about_ca_system_score_gemma":0.0004234372,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000004095934,"about_ca_topic_score_gemma":0.00000923711,"domain_scores_codex":[0.9984182,0.00009188303,0.0005552332,0.0004779891,0.0001900204,0.0002666554],"domain_scores_gemma":[0.9984699,0.0001190079,0.0001265777,0.0006601292,0.00027316,0.0003512099],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001764528,0.01788462,0.1193248,0.001350591,0.002887318,0.002109184,0.01728729,0.00001226109,0.05311349,0.03037286,0.2363199,0.5175731],"study_design_scores_gemma":[0.003955879,0.0006616496,0.05526629,0.0001432312,0.0002408531,0.0001997259,0.000228643,0.000848877,0.01379277,0.0001958144,0.9241956,0.0002706563],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9539167,0.0004929391,0.001275843,0.02098263,0.001158805,0.001794951,0.0001834559,0.0003134643,0.01988125],"genre_scores_gemma":[0.9772455,0.0001238856,0.003604647,0.003512965,0.0006532663,0.0002376142,0.0007447784,0.00003967471,0.01383769],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6878757,"threshold_uncertainty_score":0.9778979,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08590255119467977,"score_gpt":0.4106181409906178,"score_spread":0.324715589795938,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}